Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Ibrutinib plus venetoclax for the first-line treatment of CLL/SLL: Results from the CAPTIVATE study

Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia
Ibrutinib plus venetoclax for the first-line treatment of CLL/SLL: Results from the CAPTIVATE study ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )
18 Dec 2019

ELEVATE TN: Comparing acalabrutinib monotherapy or in combination with obinutuzumab in treatment-naïve CLL

Dr Jeff Sharman - Willamette Valley Cancer Institute and Research Center, Eugene, USA
ELEVATE TN: Comparing acalabrutinib monotherapy or in combination with obinutuzumab in treatment-naïve CLL ( Dr Jeff Sharman - Willamette Valley Cancer Institute and Research Center, Eugene, USA )
17 Dec 2019

PRIMO: Optimising the dose of duvelisib in patients with R/R peripheral T-cell lymphoma

Dr Steven Horwitz - Memorial Sloan Kettering Cancer Center, New York, USA
PRIMO: Optimising the dose of duvelisib in patients with R/R peripheral T-cell lymphoma ( Dr Steven Horwitz - Memorial Sloan Kettering Cancer Center, New York, USA )
17 Dec 2019

Umbralisib, ublituximab and venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia

Dr Paul Barr - Wilmot Cancer Institute, University of Rochester Medical Center
Umbralisib, ublituximab and venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia ( Dr Paul Barr - Wilmot Cancer Institute, University of Rochester Medical Center )
17 Dec 2019

GLS1 dependency in MYC over-expressing multiple myeloma: New target for therapy?

Dr Salomon Manier - Dana-Farber Cancer Institute, Boston, USA
GLS1 dependency in MYC over-expressing multiple myeloma: New target for therapy? ( Dr Salomon Manier - Dana-Farber Cancer Institute, Boston, USA )
17 Dec 2019

FiTNEss: Investigating frailty-adjusted therapy in transplant non-eligible patients with NDMM

Prof David Cairns - University of Leeds, Leeds, UK
FiTNEss: Investigating frailty-adjusted therapy in transplant non-eligible patients with NDMM ( Prof David Cairns - University of Leeds, Leeds, UK )
17 Dec 2019

Weekly wKRd-D in newly diagnosed multiple myeloma achieves unprecedented results

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
Weekly wKRd-D in newly diagnosed multiple myeloma achieves unprecedented results ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )
13 Dec 2019

Dasatinib vs imatinib for paediatric Ph ALL

Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA
Dasatinib vs imatinib for paediatric Ph ALL ( Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA )
12 Dec 2019

Study of quadruple combination for induction resistant myeloma reveals novel immune checkpoints

Dr Yael Cohen - Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Study of quadruple combination for induction resistant myeloma reveals novel immune checkpoints ( Dr Yael Cohen - Tel Aviv Sourasky Medical Center, Tel Aviv, Israel )
12 Dec 2019

KRd vs KTd followed by carfilzomib maintenance in newly diagnosed MM

Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria
KRd vs KTd followed by carfilzomib maintenance in newly diagnosed MM ( Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria )
12 Dec 2019

Moxetumomab pasudotox-tdfk in heavily retreated r/r hairy cell leukaemia

Dr Robert Kreitman - National Cancer Institute, Bethesda, USA
Moxetumomab pasudotox-tdfk in heavily retreated r/r hairy cell leukaemia ( Dr Robert Kreitman - National Cancer Institute, Bethesda, USA )
12 Dec 2019

Azacitidine plus nivolumab in older adults with AML or MDS

Prof Annette Hay - Queen's University, Ontario, Canada
Azacitidine plus nivolumab in older adults with AML or MDS ( Prof Annette Hay - Queen's University, Ontario, Canada )
12 Dec 2019